• Loading stock data…

Immunocore to present at the 5th Annual Evercore ISI HealthCONx Conference

Last Updated on November 23, 2022 by GlobeNewsWire

Immunocore to present at the 5th Annual Evercore ISI HealthCONx Conference

(OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 23 November 2022) Immunocore Holdings Plc (Nasdaq: IMCR), a commercial-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, infection and autoimmune disease, today announced that management will participate in a fireside chat at the 5th Annual Evercore ISI HealthCONx Conference.

The presentation is scheduled for Wednesday, November 30, 2022, at 8:25 a.m. Eastern Time (ET).

The presentation will be webcast live during the conference and will be available in the ‘Investors’ section of Immunocore’s website at http://www.immunocore.com. A replay of the presentation will be made available for a limited time.

##

About Immunocore

Immunocore is a commercial-stage biotechnology company pioneering the development of a novel class of TCR bispecific immunotherapies called ImmTAX – Immune mobilizing monoclonal TCRs Against X disease – designed to treat a broad range of diseases, including cancer, autoimmune, and infectious disease. Leveraging its proprietary, flexible, off-the-shelf ImmTAX platform, Immunocore is developing a deep pipeline in multiple therapeutic areas, including five clinical stage programs in oncology and infectious disease, advanced pre-clinical programs in autoimmune disease and multiple earlier pre-clinical programs. Immunocore’s most advanced oncology TCR therapeutic, KIMMTRAK, has been approved for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma (mUM) in the United States, European Union, Canada, Australia and the United Kingdom, having demonstrated an overall survival benefit in a randomized Phase 3 clinical trial in mUM, a cancer that has historically proven to be insensitive to other immunotherapies.

CONTACT:

Immunocore S?bastien Desprez, Head of CommunicationsT: +44 (0) 7458030732E: sebastien.desprez@immunocore.comFollow on Twitter: @Immunocore

Consilium Strategic Communications (corporate and financial)Mary-Jane Elliott/ Chris Welsh/Jessica HodgsonT: +44 (0)203 709 5700E: Immunocore@consilium-comms.com

Investor Relations Clayton Robertson, Head of Investor RelationsT: +1 215-384-4781E: ir@immunocore.com




Print Friendly, PDF & Email
Spread the word

Reader Interactions

This site uses Akismet to reduce spam. Learn how your comment data is processed.

%d bloggers like this: